Key result
Wireless UV photoactivation of caged AaH-II enhances late sodium current and modulates cardiac electrical activity.
Why the study?
Precise spatiotemporal control of pharmacological compounds in cardiac tissue remains an unmet challenge, and translating photopharmacology to the beating heart requires wireless light delivery to a moving, soft, and electrically active organ.
Does wireless photoactivation of caged AaH-II peptide using an implantable optoelectronic device modulate cardiac electrical activity in a beating heart?
Does wireless photoactivation of caged AaH-II peptide using an implantable optoelectronic device modulate cardiac electrical activity in a beating heart?
Demonstrates the first in vivo proof-of-concept for wireless, light-triggered photoactivation of a caged peptide to remotely and temporally modulate cardiac electrical activity in a beating heart.
Answers are grounded in this paper and cite their sources.
Demonstrates wireless photopharmacology feasibility in the beating heart; leaves open clinical translation pending further validation.
Precise spatiotemporal control of pharmacological compounds in cardiac tissue remains an unmet challenge. Systemic drug administration poorly reproduces the localized and transient nature of cardiac events. Photopharmacology, in which light controls drug activity, offers a compelling solution, but its translation to the beating heart requires wireless light delivery to a moving, soft, and electrically active organ. Here, we demonstrate the first in vivo use of a wireless device to photoactivate a peptide that modulates cardiac excitability. Using a flexible, battery-free implantable optoelectronic device, we achieved light-triggered uncaging of AaH-II*, a natural peptide that enhances the late sodium current. We first validated the caged peptide in vitro and ex vivo, showing that caging suppresses its activity and that UV illumination rapidly restores it. In vivo, wireless photoactivation produced a clear modulation of cardiac electrical activity, as monitored by electrocardiography. This work establishes device-based peptide photomodulation as a strategy for remote, temporally controlled pharmacological intervention in the heart. More broadly, it provides a new platform for probing cardiac excitability and developing region-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Dereli et al. (2026) studied Cardiac excitability / late sodium current (INaL) modulation. Wireless implantable optoelectronic device for UV photoactivation (uncaging) of caged AaH-II peptide was evaluated on Modulation of cardiac electrical activity monitored by electrocardiography. Wireless UV photoactivation of caged AaH-II peptide via an implantable device enhanced late sodium current and modulated in vivo cardiac electrical activity on ECG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: